https://www.selleckchem.com/pr....oducts/Decitabine.ht
herapeutic options. We discover that a subset of ovarian cancers are intrinsically sensitive to pharmacological PARG blockade, including drug-resistant disease, underpinned by a common mechanism of replication catastrophe. We explore the use of a transcript-based biomarker, and provide insight into the design of future clinical trials of PARGi in patients with ovarian cancer. However, our results highlight the complexity of developing a predictive biomarker for PARGi sensitivity. We discover that a subset of ovarian cancers are intri
Like
Comment
Share
